# A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

> **NCT01379300** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (actual)

## Conditions studied

- Thrombosis

## Interventions

- **DRUG:** dabigatran etexilate
- **DRUG:** rivaroxaban

## Key facts

- **NCT ID:** NCT01379300
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379300, "A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01379300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*